6686 Blood Cancer Peer Review Journals | Open Access Journals

Accounting & Marketing

ISSN: 2168-9601

Open Access

6686 Blood Cancer Peer Review Journals

Over the last years, there has been nice progress within the treatment of myeloma with several new agents and combos having been approved and being currently habitually incorporated into treatment methods. As a result, patients ar experiencing advantages in terms of survival and higher tolerance. However, the multitude of treatment choices additionally presents a challenge to pick the simplest choices tailored to the precise patient state of affairs. Lenalidomide is progressively being employed as a part of frontline medical care in new diagnosed myeloma. This agent is often administered till unwellness progression. it's presently unclear, the way to best manage patients, UN agency relapse whereas receiving lenalidomide as a part of their frontline treatment. we tend to conducted a review to summarize the on the market proof during this setting. Our outline shows that there ar only a few information from current trials testing new combos supported carfilzomib, pomalidomide, or daratumumab that address this specific patient population. Our review is aimed to summarize the on the market proof to help treatment deciding and to lift awareness of this lack of information to encourage more analyses and also the incorporation of sequencing queries in future trial styles.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Business & Management

Google Scholar citation report
Citations: 412

Accounting & Marketing received 412 citations as per Google Scholar report

Accounting & Marketing peer review process verified at publons

Indexed In

arrow_upward arrow_upward